#Singapore #lupus therapy #Tikva Allocell #CD19 CAR T-cell

Tikva Allocell Showcases Innovative Research at ACR Convergence 2026

Tikva Allocell Pte. Ltd., a pioneering biotechnology firm, is making strides in the field of cellular therapies targeted towards cancer and autoimmune diseases. The company's recent breakthrough research has earned a prestigious slot for oral presentation at the upcoming ACR Convergence 2026, scheduled for November 6-11 in Orlando, Florida. The forthcoming presentation will focus on their preclinical study regarding CD19.SB9.CAR-EBVST, a promising therapy aimed at systemic lupus erythematosus (SLE).

Presentation Overview

The title of the presentation is "Preclinical Evaluation of a Lymphodepletion-free Approach for the Treatment of SLE Using an Armored Allogeneic CD19 Chimeric Antigen Receptor Expressing Epstein-Barr Virus Specific T cell Therapy." Dr. Marvin Chew, a senior research scientist at Tikva Allocell, is set to lead the discussion. The presentation will highlight the potential of Tikva's allogeneic CD19 CAR T-cell strategy as an innovative treatment that may eliminate the need for lymphodepletion in SLE patients.

Ivan Horak, MD, the Founder and CEO of Tikva, expressed enthusiasm about the recognition, stating, "This research being selected for oral presentation exemplifies the promise our CD19.SB9.CAR-EBVST program holds. This achievement reflects our ongoing commitment to advancing allogeneic CAR T-cell therapies for patients grappling with significant unmet medical needs."

Insights into Tikva's Technology

Tikva's therapeutic platform utilizes Epstein-Barr virus-specific T cells (EBVST) to develop engineered cell therapies. Their research endeavors extend beyond oncology, including studies focused on autoimmune diseases like systemic lupus erythematosus. This approach harnesses donor-derived T cells that possess unique properties, allowing them to target autoimmune conditions effectively.

The upcoming ACR Convergence 2026 will serve as a vital platform for Tikva to share knowledge and present data to the rheumatology community, aimed at improving treatment accessibility for patients suffering from debilitating conditions.

A Vision for the Future

The innovative CD19.SB9.CAR-EBVST therapy is part of a broader pipeline at Tikva Allocell, which is centered on enhancing patient care with off-the-shelf T-cell therapies. The company's existing portfolio demonstrates a potential shift in how autoimmune diseases are approached and treated, indicating a promising future in immunotherapy.

The potential of utilizing allogeneic virus-specific T cells in this context signals a paradigm shift in treatment methodologies, moving toward more effective, tailored solutions for patients with distinct health challenges. Tikva's ongoing commitment to research and development is a testament to its vision in the biotech space, particularly for patients with major unmet therapeutic needs.

As the presentation date draws closer, the biotechnology industry and the SLE community eagerly anticipate the insights that will emerge, hoping that solutions enhancing patient outcomes will soon come to fruition.